This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
National Healthcare Quality Report 2003.
Percent of heart failure patients with left ventricular systolic dysfunction prescribed ACE inhibitor at discharge.
Centers for Medicare and Medicaid Services, Health Care Quality Improvement Program (HCQIP) Quality Indicator.
1.43a Percent of heart failure patients with left ventricular systolic dysfunction prescribed ACE inhibitor at discharge, United States, 2000 - 2001.
1.43b Percent of heart failure patients with left ventricular systolic dysfunction prescribed ACE inhibitor at discharge, by state, 2000 – 2001.
Centers for Medicare and Medicaid Services, Medicare Quality Improvement Organization Program. Data are from a systematic random sample of up to 800 inpatient records per state.
Medicare live discharges meeting both of the following criteria:
Principal diagnosis of heart failure (ICD-9 codes 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428.x).
Documented left ventricular function evaluation not consistent with left ventricular systolic dysfunction (ejection fraction less than 40% or equivalent narrative description).
Subset of denominator who meet at least one of the following three conditions:
On angiotensin converting enzyme inhibitor (ACEI) at discharge.
Chart documentation of one or more of the following contraindications to ACEI use: moderate or severe aortic stenosis; or bilateral renal artery stenosis; or history of angioedema, hives or severe rash with ACEI use.
Physician documentation of any specific reason why ACEI is not used.
Excludes patients transferred to another acute care hospital; patients who expired; patients who left against medical advice; patients on dialysis; patients on angiotensin-receptor blocker (ARB), but not ACEI at discharge; patients participating in a clinical trial testing alternatives to ACEIs as first-line heart failure therapy. This measure is also a Joint Commission on Accreditation of Healthcare Organizations core measure.
Return to Previous Measure
Return to Measures Specifications Appendix
Proceed to Next Measure
Return to Contents